HCA Healthcare enters the week after its Q1 earnings print with options markets running unusually defensive, short sellers rebuilding positions at a pace not seen in months, and a coordinated analyst target-price reset that leaves the stock trading well below where Wall Street was pitching it just six weeks ago.
Options positioning has turned markedly more cautious than the recent norm. The put/call ratio reached 1.148 on May 5 — nearly two standard deviations above the 20-day mean of 0.949 and the highest defensive reading in several weeks. That z-score of 1.91 places the current PCR in rarefied territory relative to the past year's range of 0.65 to 1.33, pointing to heavier demand for downside protection from an options market that spent most of April below parity.
Short interest has been building steadily since early April, and the trend is hard to ignore. SI as a percentage of free float climbed from roughly 2.3% in late March to 2.8% by early May — a 20% rise over the period. The position peaked around 2.9% on April 30 and eased slightly on May 5, but the broader direction is clear: short sellers added meaningfully into and after the earnings print on April 24. The borrow market remains relaxed, however. Cost to borrow is running at just 0.39% annually, down more than 26% on the week and 22% lower than a month ago. Availability is also loose, suggesting the short build reflects a genuine directional view rather than a technical squeeze dynamic.
The earnings reaction itself set the tone. The April 24 Q1 print sent the stock down nearly 6% on the day and another 3% over the following five days, for a total five-day loss of roughly 8.6%. The bears' case is well-documented: a $180 million EBITDA headwind from flu and weather effects, a 15% decline in Exchange admissions, and a $150 million drag from HIX pressures. The one-month price decline now stands at 9.1%, with the stock at $428.79, though it clawed back 0.4% on May 5 alone. Peer THC gained 5.3% on the week while UHS added 1.8%, suggesting some of HCA's underperformance is stock-specific rather than purely sector-driven.
The Street's reaction to Q1 was consistent: virtually every covering analyst lowered their price target on April 27 while leaving ratings unchanged. TD Cowen cut to $500 from $561, Barclays moved to $496 from $551, RBC dropped to $534 from $593, and Wells Fargo trimmed to $436 from $481 — all maintaining their existing ratings. The consensus mean target now sits at $513, implying roughly 20% upside from current levels. Bulls point to HCA's position as the largest US acute-care hospital operator, with newly approved state-directed payment programs and an expanding outpatient network expected to support 2026 targets despite the Q1 stumble. Bears argue that higher labour costs, rising professional fees, and the residual headwind from exchange admissions could compress margins further. The EV/EBITDA multiple is tracking around 9x on a trailing basis — not demanding for a business generating over $19 billion in quarterly revenue with an EBITDA margin near 20%. The 30-day PE compression of roughly 1.8 turns reflects the market's adjustment post-earnings.
The institutional picture shows broad, stable ownership rather than acute selling pressure. Vanguard and BlackRock together hold nearly 12% of shares, with the latter adding about 212,000 shares as of April 30. FMR built a more notable position — adding over 1.5 million shares through March 31. Insider activity is less compelling near-term, with all recent disclosed trades dated to mid-February and consisting solely of sells by legal, HR, and accounting officers. These look like programmatic disposals rather than conviction statements, and the trades occurred at prices well above the current level.
What to watch next: the pace of the short rebuild around the 2.8–2.9% range and whether options markets normalise their put/call ratio as the post-earnings overhang fades — any easing there would signal the defensive positioning is unwinding.
See the live data behind this article on ORTEX.
Open HCA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
